No connection

Search Results

AROW vs HQL

AROW
Arrow Financial Corporation
NEUTRAL
Price
$32.48
Market Cap
$534.1M
Sector
Financial Services
AI Confidence
78%
HQL
Abrdn Life Sciences Investors
BULLISH
Price
$17.56
Market Cap
$534.0M
Sector
Financial Services
AI Confidence
75%

Valuation

P/E Ratio
AROW
12.26
HQL
6.29
Forward P/E
AROW
7.5
HQL
--
P/B Ratio
AROW
1.24
HQL
1.01
P/S Ratio
AROW
3.37
HQL
275.47
EV/EBITDA
AROW
--
HQL
--

Profitability

Gross Margin
AROW
0.0%
HQL
100.0%
Operating Margin
AROW
40.7%
HQL
-346.83%
Profit Margin
AROW
27.76%
HQL
4415.74%
ROE
AROW
10.56%
HQL
17.59%
ROA
AROW
1.0%
HQL
-0.43%

Growth

Revenue Growth
AROW
37.0%
HQL
-69.9%
Earnings Growth
AROW
216.5%
HQL
259.4%

Financial Health

Debt/Equity
AROW
--
HQL
--
Current Ratio
AROW
--
HQL
0.73
Quick Ratio
AROW
--
HQL
0.71

Dividends

Dividend Yield
AROW
3.69%
HQL
12.76%
Payout Ratio
AROW
43.02%
HQL
65.23%

AI Verdict

AROW NEUTRAL

AROW's Piotroski F-Score of 3/9 indicates weak financial health, signaling potential distress in operational efficiency and capital structure. The absence of an Altman Z-Score raises concern about bankruptcy risk, especially given the lack of available debt and liquidity metrics. Despite strong profitability (27.76% margin) and explosive earnings growth (216.5% YoY), the stock trades at a premium to its Graham Number ($39.57) and intrinsic value ($78.17), suggesting overvaluation relative to conservative valuation models. The technical trend is bearish, and insider activity is neutral, with no recent trades. Analyst consensus is a hold, reflecting cautious sentiment.

Strengths
Exceptional profit margin of 27.76% and high operating margin of 40.70%
Impressive earnings growth of 216.5% YoY and 213.5% Q/Q
Strong historical earnings beat rate (3 out of last 4 quarters) with average surprise of 11.81%
Risks
Piotroski F-Score of 3/9 indicates weak financial health and operational instability
No Altman Z-Score available, raising unquantified bankruptcy risk
Stock trades below intrinsic value ($78.17) but above Graham Number ($39.57), suggesting overvaluation relative to conservative benchmarks
HQL BULLISH

HQL presents as a deep-value opportunity, anchored by a stable Piotroski F-Score of 6/9 and a significant valuation gap, with a current price of $17.56 trading well below its Graham Number ($33.01) and Intrinsic Value ($82.31). While the company exhibits severe operational anomalies—specifically a -69.90% revenue collapse and a deeply negative operating margin—the massive earnings growth and low P/E ratio (6.29) suggest the entity is benefiting from significant investment gains rather than core fee income. The high dividend yield of 12.76% is supported by a sustainable payout ratio, though the bearish technical trend (10/100) suggests a period of consolidation or price correction is underway.

Strengths
Extreme undervaluation relative to Graham Number ($33.01) and Intrinsic Value ($82.31)
Very low P/E ratio (6.29) compared to the sector average of 36.83
Strong dividend yield of 12.76% with a manageable payout ratio (65.23%)
Risks
Severe revenue decline (-69.90% YoY) indicating a collapse in core business growth
Poor operational efficiency with an operating margin of -346.83%
Liquidity risk evidenced by a current ratio of 0.73 (below 1.0)

Compare Another Pair

AROW vs HQL: Head-to-Head Comparison

This page compares Arrow Financial Corporation (AROW) and Abrdn Life Sciences Investors (HQL) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile